BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
NVS upcoming catalysts
Novartis Pharmaceuticals: 11 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 30 readout(s) and 12 FDA event(s). Subscribe to NVS (.ics).
Drugs: Iptacopan, AAA617, JDQ443, KAE609, Remibrutinib, Alpelisib, Fulvestrant, Ribociclib, KLU156, Teriflunomide, INE963, JSB462, Abiraterone, Enzalutamide, AAA517, Piflufolastat F 18, ARPI, ADT, Rituximab, Inclisiran, TNO155, tislelizumab, LEE011, LXH254, LTT462, Trametinib, 68Ga-PSMA-11, Corticosteroids, cetuximab, docetaxel
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-03 est. | P2 | Novartis Pharmaceuticals NVS | NCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | 168 |
| 2026-12-23 est. | P2 | Novartis Pharmaceuticals NVS | NCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | Prostatic Neoplasm | active not recruiting | 49 |
| 2026-12-30 est. | P2 | Novartis Pharmaceuticals NVS | NCT06388941 Iptacopan in Patients With ANCA Associated Vasculitis | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | active not recruiting | 84 |
| 2027-01-16 est. | P3 | Novartis Pharmaceuticals NVS | NCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Acute Coronary Syndrome | active not recruiting | 305 |
| 2027-01-25 est. | P1/P2 | Novartis Pharmaceuticals NVS | NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung | active not recruiting | 344 |
| 2027-01-28 est. | P3 | Novartis Pharmaceuticals NVS | NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatm | Breast Cancer | active not recruiting | 210 |
| 2027-01-29 est. | P2 | Novartis Pharmaceuticals NVS | NCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women Wit | Breast Neoplasms | active not recruiting | 69 |
| 2027-01-29 est. | P3 | Novartis Pharmaceuticals NVS | NCT04817618 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | C3G | recruiting | 98 |
| 2027-02-01 est. | P2 | Novartis Pharmaceuticals NVS | NCT02934568 Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Can | active not recruiting | 22 |
| 2027-02-02 est. | P2 | Novartis Pharmaceuticals NVS | NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Melanoma | active not recruiting | 134 |
| 2027-02-04 est. | P2 | Novartis Pharmaceuticals NVS | NCT07811908 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) | Uncomplicated Plasmodium Falciparum Malaria | recruiting | 120 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | Novartis Pharmaceuticals NVS | NCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | Metastatic Castration Resistant Prostate Cancer (mCRPC) | active not recruiting | 7 |
| 2026-11-06 est. | P2 | Novartis Pharmaceuticals NVS | NCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 23 |
| 2026-11-03 est. | P3 | Novartis Pharmaceuticals NVS | NCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response | Chronic Spontaneous Urticaria | active not recruiting | 100 |
| 2026-10-29 | P3 | Novartis Pharmaceuticals NVS | NCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) | active not recruiting | 226 |
| 2026-10-26 est. | P3 | Novartis Pharmaceuticals NVS | NCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in | Coronary Artery Disease | active not recruiting | 610 |
| 2026-10-15 | P3 | Novartis Pharmaceuticals NVS | NCT05900141 An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Hyperlipoproteinemia (a) | terminated | 41 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-09-24 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus; Lupus Nephritis | completed | 21 |
| 2026-09-17 | P2 | Novartis Pharmaceuticals NVS | NCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | Hypertension | active not recruiting | 396 |
| 2026-09-03 | P3 | Novartis Pharmaceuticals NVS | NCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | terminated | 95 |
| 2026-08-19 | P2 | Novartis Pharmaceuticals NVS | NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Age-Related Macular Degeneration | completed | 168 |
| 2026-07-22 | P3 | Novartis Pharmaceuticals NVS | NCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | active not recruiting | 1007 |
| 2026-07-21 | P3 | Novartis Pharmaceuticals NVS | NCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Relapsing Multiple Sclerosis | active not recruiting | 1000 |
| 2026-07-16 | P3 | Novartis Pharmaceuticals NVS | NCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | Cardiovascular Disease and Lipoprotein(a) | completed | 8323 |
| 2026-06-23 | P2 | Novartis Pharmaceuticals NVS | NCT06643481 A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | active not recruiting | 251 |
| 2026-06-17 | P2 | Novartis Pharmaceuticals NVS | NCT07811882 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) | Uncomplicated Plasmodium Falciparum Malaria | completed | 95 |
| 2026-06-10 | P1/P2 | Novartis Pharmaceuticals NVS | NCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | IgA Nephropathy | completed | 103 |
| 2026-06-09 est. | P2 | Novartis Pharmaceuticals NVS | NCT05750628 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria | Uncomplicated Plasmodium Falciparum Malaria | recruiting | 327 |
| 2026-05-12 | P1/P2 | Novartis Pharmaceuticals NVS | NCT03374657 A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa | Retinitis Pigmentosa | completed | 12 |
| 2026-05-11 | P3 | Novartis Pharmaceuticals NVS | NCT05976243 A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamine | Chronic Inducible Urticaria | active not recruiting | 362 |
| 2026-04-11 | P3 | Novartis Pharmaceuticals NVS | NCT04889430 Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy | Atypical Hemolytic Uremic Syndrome | completed | 34 |
| 2026-03-25 | P3 | Novartis Pharmaceuticals NVS | NCT06267560 Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | completed | 422 |
| 2026-03-25 | P3 | Novartis Pharmaceuticals NVS | NCT04926818 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis (MS) | active not recruiting | 129 |
| 2026-03-19 | P2 | Novartis Pharmaceuticals NVS | NCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Lupus Nephritis | terminated | 81 |
| 2026-02-25 | P2 | Novartis Pharmaceuticals NVS | NCT05996835 Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) | Acute Kidney Injury Due to Sepsis | completed | 316 |
| 2026-02-24 | P3 | Novartis Pharmaceuticals NVS | NCT05380453 Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | Giant Cell Arteritis | completed | 151 |
| 2026-02-20 | P3 | Novartis Pharmaceuticals NVS | NCT05648968 A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | active not recruiting | 90 |
| 2026-02-17 | P2 | Novartis Pharmaceuticals NVS | NCT06293365 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled S | Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritis | active not recruiting | 155 |
| 2026-02-03 | P2 | Novartis Pharmaceuticals NVS | NCT05592990 A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy | Achilles Tendinopathy | completed | 45 |
| 2026-01-28 | P3 | Novartis Pharmaceuticals NVS | NCT06869785 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | Relapsing Multiple Sclerosis (RMS) | active not recruiting | 196 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.